Oncology
Continuity is designed before supply begins.
NovaPharm's oncology model connects formulation, evidence, qualified sourcing, condition control and UK market-readiness decisions without asserting current product availability or clinical authority.
The operating question
Can the evidence, product and accountable parties remain aligned through every hand-off?
A positive commercial signal is not enough. Product rights, formulation, source, quality, permissions, handling and release responsibilities must be read together.
Readiness
Five dependencies that should be visible early.
- 01
Product and rights
Establish the product identity, rights position and intended role.
- 02
Formulation and evidence
Identify technical, stability, manufacturing and documentation dependencies.
- 03
Qualified source
Assess the accountable manufacturer or authorised supply route.
- 04
Condition control
Connect requirements to packaging, lane, monitoring and exception review.
- 05
UK pathway
Make applicable regulatory, quality and market-entry decisions explicit.
Controlled handling
A temperature range alone is not a control system.
Where condition sensitivity applies, product requirements must connect to packaging, qualification, monitoring, custody, exception review and release responsibility.
Development to access
Preserve context through each accountable hand-off.
- 01Programme evidence
- 02Product readiness
- 03Qualified source
- 04Regulatory path
- 05Controlled release
Qualified collaboration
Bring evidence, authority and a defined role.
A first conversation is an opportunity review, not qualification, approval or a commitment to supply.
- Product and dossier owners
- Qualified manufacturers and CMO/CDMOs
- Authorised supply partners
- Specialist quality and regulatory providers